NASDAQ · PASG
Healthcare · Biotechnology
$3.86
Down-$0.08 (-1.95%)
Updated Oct 9, 2026, 1:56 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PASG
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
PASG closed at $3.86 after 20 trading sessions, down 22.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $4.00 | $4.05 | $3.7625 | $3.855 | 14.06K |
| Oct 6, 2026 | $4.13 | $4.2899 | $4.08 | $4.08 | 6.57K |
| Oct 5, 2026 | $4.05 | $4.19 | $4.05 | $4.09 | 17.93K |
| Oct 2, 2026 | $4.29 | $4.44 | $4.11 | $4.12 | 17.05K |
| Oct 1, 2026 | $4.50 | $4.7344 | $4.20 | $4.201 | 26.48K |
| Sep 30, 2026 | $4.59 | $4.67 | $4.3701 | $4.50 | 28.93K |
| Sep 29, 2026 | $4.61 | $4.88 | $4.61 | $4.63 | 24.75K |
| Sep 28, 2026 | $4.79 | $5.0717 | $4.52 | $4.675 | 18.65K |
| Sep 25, 2026 | $4.78 | $4.85 | $4.61 | $4.80 | 8.69K |
| Sep 24, 2026 | $4.96 | $5.03 | $4.785 | $4.80 | 6.66K |
| Sep 23, 2026 | $4.86 | $5.05 | $4.82 | $5.00 | 3.44K |
| Sep 22, 2026 | $4.887 | $4.95 | $4.73 | $4.95 | 24.1K |
| Sep 21, 2026 | $4.76 | $4.83 | $4.665 | $4.83 | 117.63K |
| Sep 18, 2026 | $4.93 | $4.935 | $4.66 | $4.75 | 21.24K |
| Sep 17, 2026 | $4.98 | $5.04 | $4.75 | $5.04 | 3.32K |
| Sep 16, 2026 | $4.74 | $4.915 | $4.74 | $4.86 | 18.04K |
| Sep 15, 2026 | $4.83 | $4.845 | $4.70 | $4.77 | 9.82K |
| Sep 14, 2026 | $4.91 | $5.03 | $4.81 | $4.86 | 30.12K |
| Sep 11, 2026 | $4.97 | $5.13 | $4.90 | $5.00 | 7.89K |
| Sep 10, 2026 | $4.99 | $5.2151 | $4.90 | $4.985 | 28.58K |
The latest Smart Investors Daily articles mentioning PASG.
Company
Market Activity
Research & News
PASG research
Company profile and research snapshot.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 21, 2026 | TD Cowen | Hold | — |
| Apr 21, 2026 | Oppenheimer | Outperform | — |
| Apr 21, 2026 | Wedbush | Neutral | — |
| Apr 21, 2026 | Chardan Capital | Neutral | — |
| Mar 31, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst consensus estimate of $(2.68) by 52.5 percent. This is a 2.25 percent decrease over losses of $(4.00) per share from the
defenseworld.net · Dec 7, 2025
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Insider and Institutional Ownership 53.5% of Passage Bio
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PASG.
